Cancer letters, 2009-02, Vol.274 (2), p.271-278
2009
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model
- Ist Teil von
- Cancer letters, 2009-02, Vol.274 (2), p.271-278
- Ort / Verlag
- Ireland: Elsevier Ireland Ltd
- Erscheinungsjahr
- 2009
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Abstract Clinically obtainable concentrations of zoledronic acid (ZOL) inhibited the production of vascular endothelial growth factor and reduced the migration, adhesion, and invasiveness of osteosarcoma (OS) cells in vitro . The in vivo effects of ZOL were investigated by using a murine model of spontaneous lung metastasis. The higher dose of ZOL (80 μg/kg three times/week) inhibited the growth of OS at the primary site, accompanied by inhibition of neovascularization in the tumor. Interestingly, while the lower dose of ZOL (80 μg/kg once a week) could not inhibit the growth of OS at the primary site, it significantly prevented lung metastasis.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0304-3835eISSN: 1872-7980DOI: 10.1016/j.canlet.2008.09.026Titel-ID: cdi_proquest_miscellaneous_66825099
- Format
- –
- Schlagworte
- Animals, Cell adhesion & migration, Cell Proliferation - drug effects, Diphosphonates - pharmacology, Disease Models, Animal, Dose-Response Relationship, Drug, Hematology, Oncology and Palliative Medicine, Imidazoles - pharmacology, Lung Neoplasms - metabolism, Lung Neoplasms - prevention & control, Lung Neoplasms - secondary, Medical research, Metastasis, Mice, Molecular weight, Neovascularization, Osteosarcoma, Osteosarcoma - metabolism, Osteosarcoma - pathology, Protein Prenylation, Rodents, Vascular endothelial growth factor, Vascular Endothelial Growth Factor A - biosynthesis, Zoledronic acid